

## Special Issue

# Molecular and Technological Advances in the Diagnosis and Therapy of Cardiovascular Diseases

### Message from the Guest Editor

Atherosclerotic cardiovascular diseases (ASCVDs) are the leading cause of morbidity and mortality in the Western world. The escalating global prevalence of ASCVDs necessitates modern advancements in molecular diagnostics and technology. Primary prevention strategies should prioritize the early identification of atherosclerosis. This is a very demanding process involving genetic, biochemical, pathophysiological and cardiovascular imaging studies, which will enable personalized treatment approaches. Similarly, secondary prevention of ASCVDs should follow with the principles of precision medicine determining the extent of follow-up and the intensity of therapy. Multiple and complex pathophysiologic mechanisms are involved in atherosclerosis progression. Hence, there is still an increasing need to develop and apply more personalized diagnostic tests (molecular and imaging) and therapeutic regimens for ASCVDs. We invite the submission of research and narrative reviews focusing on basic atherosclerosis studies to advance prevention, diagnosis, risk assessment, and treatment through personalized medicine.

---

### Guest Editor

Dr. Nikolaos Kadoglou

Medical School, University of Cyprus, Nicosia CY2024, Cyprus

---

### Deadline for manuscript submissions

31 March 2025



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/183384](https://mdpi.com/si/183384)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).